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Abstract
Low molecular weight heparin (LMWH) is being investigated as a potential preventative ther-
apy against preeclampsia. There is evidence suggesting that LMWH may prevent preeclampsia
through anticoagulation-independent mechanisms. In this study, we compared the in vitro placen-
tal, endothelial, and anti-inflammatory effects of an LMWH (dalteparin) with a nonanticoagulant,
glycol-split heparin derivative (gsHep). In contrast with dalteparin, gsHep did not interact with
antithrombin III, possess significant anti-Factor Xa activity, or significantly prolong in vitro plasma
clotting time. However, dalteparin and gsHep were otherwise mechanistically similar, both inter-
acting with soluble fms-like tyrosine kinase-1 (sFlt1) and promoting release of the pro-angiogenic
protein placental growth factor, but not the antiangiogenic sFlt1, from healthy placental villous
explants. Placental explant media pretreated with dalteparin or gsHep significantly stimulated en-
dothelial cell tube formation compared to untreated explants. Lastly, dalteparin and gsHep both
significantly suppressed inflammation by inhibiting complement activation and leukocyte adhe-
sion to endothelial cells that were activated using serum from preeclamptic women. Our data
suggest that nonanticoagulant heparin derivatives may be utilized as a tool to distinguish the
anticoagulation-independent mechanisms of LMWH, and provide insight into the role of anticoag-
ulation in the prevention of preeclampsia.
Summary Sentence
Nonanticoagulant derivatives of heparinmay be useful for investigating the role of anticoagulation-
independent functions of heparin for the prevention of preeclampsia.
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Introduction
Preeclampsia impacts 3–7% of all pregnancies and is character-
ized by new-onset hypertension after 20 weeks gestation with ev-
idence of organ damage [1]. Preeclampsia is often associated with
fetal growth restriction, which may necessitate iatrogenic preterm
delivery [2]. The pathogenesis of most cases of severe early-onset
preeclampsia (clinical presentation <34 weeks) is hypothesized to
be initiated by poor spiral artery remodeling, resulting in reduced
perfusion of the placenta that creates a local state of low oxygen
tension, high oxidative stress, increased inflammation of the pla-
cental villi, and suppression of the secretion of the pro-angiogenic
protein placenta growth factor (PlGF) into maternal blood [3]. The
damaged placenta in women with severe preeclampsia subsequently
secretes large amounts of antiangiogenic molecules, such as soluble
fms-like tyrosine kinase-1 (sFlt1), and disrupts the function of pro-
angiogenic molecules such as PlGF [4]. Hemodynamic data suggest
that this antiangiogenic state mediates the development of maternal
hypertension through widespread systemic maternal endothelial dys-
function that contributes to systemic vasoconstriction and impaired
vital organ perfusion in women with severe early-onset preeclampsia
[5].
Currently, there are limited preventative therapies for pregnant
women at high-risk of preeclampsia. Low-dose aspirin can sig-
nificantly reduce the incidence of preeclampsia; however, the ef-
fect is modest and benefits only approximately half of all cases
[6]. Several clinical trials suggest that low molecular weight hep-
arin (LMWH), which is often prescribed to pregnant women at
elevated risk of pregnancy-related venous thromboembolism, may
further reduce the rate or severity of severe preeclampsia and im-
prove fetal outcomes [7], but more recent larger trials demon-
strated no significant effect of LMWH [8, 9]. Although conflict-
ing, these clinical trials have determined that LMWH is not effec-
tive for women at risk of all types of preeclampsia, and may only
be effective for a subtype [10]. Understanding the precise molec-
ular mechanisms that mediate the beneficial effects of LMWH in
preeclampsia is therefore of critical importance, but these mecha-
nisms are thus far not well understood. Despite its general use as
an anticoagulant, there is some evidence suggesting that the po-
tential preventive effects of LMWH in preeclampsia are mediated
by nonanticoagulant mechanisms. A multicenter randomized con-
trolled clinical trial conducted with 114 women demonstrated that
LMWH reduced the recurrence of preeclampsia in high-risk preg-
nant women who were not at risk of thrombophilia [11]. In addi-
tion, daily unfractionated heparin therapy used at doses for venous
thromboembolism prophylaxis does not significantly reduce placen-
tal thrombosis [12]. Therefore, the nonanticoagulant mechanisms
of LMWH may mediate the prevention of preeclampsia, but the
relevant nonanticoagulant mechanisms have not been thoroughly
investigated.
LMWH possesses various nonanticoagulant properties that may
be relevant in the prevention of preeclampsia. In vitro studies show
that LMWHmay promote extravillous trophoblast invasion and cy-
totrophoblast proliferation [13, 14], and promote endothelial angio-
genesis [15]. Acute administration of LMWH to pregnant women at
high-risk of preeclampsia improves endothelium-dependent vasodi-
lation [16]. In addition, LMWH treatment improves angiogenesis in
the presence of antiphospholipid (aPL) antibodies [17], and prevents
aPL antibody-mediated fetal loss in a mouse model by suppressing
inflammation [18]. Prophylactic LMWH therapy could exert bene-
ficial effects on the pathogenic features of preeclampsia which often
includes poor placental development, maternal systemic endothelial
dysfunction, and inflammation.
An established chemical process called “glycol-splitting” renders
heparin nonanticoagulant by disrupting the antithrombin-binding
region (ATBR) that is required for anticoagulation [19]. The objec-
tive of the current study is to compare the LMWH dalteparin to
a nonanticoagulant LMWH compound in their ability to modulate
pathways relevant to preeclampsia pathogenesis in vitro, specifically
the placental release of angiogenic factors, endothelial angiogenesis,
and inflammatory pathways.
Materials and methods
Low molecular weight heparins
Nonanticoagulant heparin (glycol-split heparin, gsHep) was pro-
vided by Dilafor (Stockholm, Sweden), chemically generated by pe-
riodate oxidation of pig intestinal mucosa heparin, followed by al-
kaline β-oxidation of the product as previously described [20]. The
average molecular weight of gsHep was approximately 6 kDa as de-
termined by high performance gel permeation chromatography ac-
cording tomanufacturer’s data. This is similar to the averagemolecu-
lar weight distribution of dalteparin [21] (Supplementary Figure S1),
which is being used as the comparison for this study to allow direct
comparisons at the molar basis. Concentrations of dalteparin and
gsHep used for functional experiments fall within the clinical range
used for dalteparin prophylaxis and acute therapy (2–10 μg/mL,
equivalent to 0.3–1.5 anti-Factor Xa IU/mL).
Tissue culture
Human umbilical vein endothelial cells (HUVECs; Lonza, Walk-
ersville, MD, USA) were maintained in EGM-2 growth media
(CC-3162). Where appropriate for experiments, fetal bovine serum
(Wisent Inc, St-Bruno, QC, Canada) was replaced with 5% patient
serum and the heparin that was included in the growth media kit
was replaced with dalteparin or gsHep. Cells were passaged at 90%
confluency. Experiments performed on HUVECs utilized cells that
were less than passage 8. THP-1 monocytes (ATCC, Manassas, VA,
USA) were cultured in RPMI-1640 media (Thermo Fisher Scientific,
Burlington, ON, Canada) containing 10% FBS and 0.05 mM β-
mercaptoethanol as described by the manufacturer, and maintained
at a density no greater than 1.0 × 106 cells/mL.
Anticoagulant assays
The ability of the heparins to inhibit Factor Xa, the major coagula-
tion protease target of LMWHs,was assessed using the BiophenHep-
arin Anti-Xa 2-stages kit (Aniara Diagnostica, West Chester, OH)
according to manufacturer instructions for assessing purified heparin
activity, using dalteparin of known concentrations as the standard.
Activated partial thromboplastin time (aPTT) assay was performed
using the Pacific Hemostasis APTT-XL kit (Thermo Fisher Scientific)
according to manufacturer’s instructions.
Differential scanning fluorimetry
Differential scanning fluorimetry assesses the thermal stability of
proteins in the presence or absence of nonpeptide small molecules,
where a melting curve shift indicates a positive interaction [22].
Twenty microliter reaction mixtures consisting of 1.2 μg of pro-
tein, heparin (in molar excess), and 5× SYPRO Orange (Thermo
Fisher Scientific) were loaded into Biorad hard-shell 96-well PCR
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plates (Mississauga, ON, Canada). Samples were heat denatured
using a Biorad CFX96 Real-Time PCR system using a ramp configu-
ration starting at 25◦C and increasing at 1◦C/minute (min) to 95◦C.
Fluorescence was measured every 30 s using the HEX filter config-
uration. Data for each curve were fitted against a four-parameter
logistic curve to determine the melting temperature of the protein,
defined as the temperature at half-maximal fluorescence of the curve.
Recombinant sFlt1 was from BioLegend (San Diego, CA, USA), and
recombinant antithrombin III (ATIII) was from Haematologic Tech-
nologies (Essex Junction, VT, USA).
Placental villous tissue explant model
Healthy first trimester placental tissue was obtained from elective
terminations via the Mount Sinai Hospital Biobank with research
ethics board approval and written consent from the patient (REB
#11-0248-E). The placental villous explant model was employed as
previously described [13]. In brief, villous trees from placenta sam-
ples of 8–12 weeks of gestation were dissected in cold sterile PBS
and cultured in a 24-well plate containing DMEM Ham F12 media
supplemented with 1× insulin-transferrin-selenium, 1× penicillin-
streptomycin-glutamine, 0.25 μg/mL fungizone, and 500 μg/mL
gentamicin (all from Thermo Fisher Scientific). Explants were accli-
mated overnight in a humidified 37◦C incubator kept at 8% O2/5%
CO2 before treating with heparin compounds prepared in fresh me-
dia for 24 h. The treated tissues and conditioned media were stored
at –80◦C until further use. sFlt1 and PlGF ELISAs (R&D Systems,
Minneapolis, MN, USA) were used to determine protein release into
the conditioned media from control and treated explants as per man-
ufacturer’s instructions.
Quantitative polymerase chain reaction
RNA extraction and qRT-PCR was performed as described
[16]. Primers used in this study are provided in Supplementary
Table S1. Gene expression was normalized to the geometric mean of
the housekeeping genes YWHAZ, TOP1, and HPRT.
Endothelial tube formation assay
Fifty microliter of growth factor-reduced Matrigel was added to a
96-well tissue culture plate and allowed to polymerize at 37◦C for
20 min. A total of 17 000 HUVEC cells/well were seeded on top
of the Matrigel in the presence of 50% conditioned media from
untreated and treated placental explants diluted in endothelial basal
media. Cells were incubated in a humidified 37◦C incubator at 20%
O2/5% CO2 for 16 h before imaging with light microscopy and
manual analysis by ImageJ Software assessing total tube length in
the field of view.
Serum samples
Serum samples from preeclamptic patients were collected upon ad-
mission for delivery atMount Sinai Hospital (Toronto, ON) upon in-
formed consent (REB #11-0248-E). All samples were collected from
patients diagnosed with early-onset preeclampsia at 26–28 weeks
with fetal growth restriction. Specific patient characteristics are pro-
vided in Supplementary Table S2. Whole blood was collected into
BD Vacutainer SST tubes (#367988), centrifuged at 2 000 g for
15 min, and then the separated serum was stored at –80◦C until use.
Complement-mediated hemolysis assay and ELISA
Washed 5% sheep erythrocytes (Cedarlane, Burlington, ON,
Canada), in HEPES-buffered saline, which are sensitive to lysis by
activation of the classical pathway of complement [23], were mixed,
in order, with 1:100 dilution of antisheep erythrocyte IgM (Cedar-
lane), 1 mM CaCl2, 1 mMMgCl2, heparin, and 3.5% patient serum
to induce complement-mediated hemolysis. The reaction was incu-
bated for 30 min at 37◦C and stopped with 330 mM EDTA. Unlysed
cells were pelleted by centrifuging at 600 g for 5 min, and 100 μL
of the supernatant was mixed with 100 μL water in duplicates. The
absorbance of this mixture at A405nm was used to determine the
hemoglobin release into the supernatant via lysis of the erythrocytes.
In the absence of treatment, the reaction conditions resulted in 70%
lysis of erythrocytes compared to total lysis with water. For treat-
ment effects, lysis was relative to the control conditions. An aliquot
of the hemolysis reaction supernatant for C5a measurements was
stored at –80◦C until use. A C5a ELISA kit (BioLegend) was used to
measure C5a generation.
Leukocyte adhesion assay
HUVECs were seeded onto 96-well plates at a density of 50 000
cells/well and allowed to adhere overnight in the absence of hep-
arin, and then stimulated with 5% preeclamptic serum in EGM-2
media without FBS for 2 h. Following treatment, cells were washed
two times with PBS and then incubated with heparin compounds in
EGM-2 media for 1 h. Meanwhile, THP-1 cells were labeled with
calcein-AM according to manufacturer instructions and resuspended
in EGM-2 media. Following heparin incubation, labeled THP-1 cells
were added directly on top of the activated HUVECs and allowed to
adhere for 45 min. Nonadherent cells were removed through a series
of three washes with PBS, and adhered cells were quantified by mea-
suring the fluorescence intensity at 480 nm ex/520 nm em using the
Tecan Infinite M200 microplate reader (Mannedorf, Switzerland).
Values were normalized to FBS control in growth media.
Statistical analyses
All experiments were performed as technical triplicates unless other-
wise stated. Data are presented as mean ± standard error. One-way
ANOVA with Bonferroni’s post hoc was used to compare melt-
ing temperature changes in the absence or presence of treatment.
Two-way ANOVA with Bonferroni’s post hoc was used to compare
dose-dependent differences between dalteparin and gsHep. Repeated
measures ANOVA with Bonferroni’s post hoc was used to compare
the dose-dependent effect of treatment to the untreated condition.
GraphPad Prism 5.0 software (La Jolla, CA, USA) was used for
analyses and P ≤ 0.05 was considered statistically significant.
Results
Glycol-split heparin has negligible anti-FXa
and anticoagulant activity
The lack of anticoagulant properties of gsHepwas verified using clin-
ically relevant assays for coagulant activity. Using a commercially
available anti-Xa activity assay, gsHep showed negligible anti-FXa
activity in comparison with dalteparin (P< 0.001; Figure 1A). In ad-
dition, gsHep showed significantly reduced ability to prolong aPTT
fibrin clot formation, in comparison with dalteparin at concentra-
tions greater than 1 μg/mL (P < 0.001; Figure 1A). These results
confirm that gsHep has substantially reduced anticoagulant activity.
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Figure 1. Anticoagulant properties of dalteparin and gsHep. (A) Glycol-split
heparin had negligible anti-Factor Xa activity compared to dalteparin at all
concentrations tested. (B) Glycol-split heparin had significantly reduced abil-
ity to prolong aPTT clotting time compared to dalteparin at concentrations
beyond 5 μg/mL. ∗∗∗P < 0.0001 compared to dalteparin at equivalent con-
centration. aPTT, activated partial thromboplastin time. n = 3 independent
experiments.
Glycol-split heparin interacts with sFlt1 but not ATIII
Differential scanning fluorimetry was used to assess the ability of
dalteparin and gsHep to interact with various proteins (Figure 2).
Dalteparin and gsHep both induced a significant shift in the melting
curve of sFlt1, indicative of a positive interaction (P < 0.001). The
magnitude of the shift was not significantly different between dal-
teparin and gsHep (P > 0.05). Other classic heparin-binding growth
factors, such as FGF1 and FGF2, also interact with gsHep (Sup-
plementary Figure S2). While dalteparin induced a curve shift for
ATIII, no significant shift was observed in the presence of gsHep.
This confirms that gsHep does not bind ATIII.
Glycol-split heparin and dalteparin elicit similar gene
expression and protein release from first trimester
placental villous explants
Healthy first trimester placental explants were treated with dal-
teparin and gsHep to evaluate gene expression and protein release.
Dalteparin and gsHep dose-dependently downregulated placental
explant PlGF and sFLT1 mRNA (ρ < 0.001 and ρ < 0.0001, re-
spectively) compared to untreated controls (Figure 3A). mRNA of
the proliferation gene PCNA was increased with both treatments (ρ
< 0.01), suggesting the absence of toxicity. The effects between dal-
teparin and gsHep were not significantly different (P > 0.05). Con-
ditioned media from 5- and 10 μg/mL dalteparin and gsHep-treated
placental explants had elevated PlGF protein levels (ρ < 0.01), but
not sFlt1 protein levels compared to media from untreated explants
(Figure 3B). No differences in effects between dalteparin and gsHep
were observed. These results indicate that gsHep and dalteparin elicit
similar angiogenic regulator mRNA level changes and protein release
from placental villous explants.
Endothelial tube formation is stimulated by media
conditioned by gsHep-treated placenta explants
Endothelial tube formation assays were performed to evaluate the
angiogenic effect of the conditioned media from dalteparin and
gsHep treated explants. Media from 2 μg/mL dalteparin and gsHep
treated placental explants stimulated HUVEC tube formation on
Matrigel compared to media from untreated explants, increasing the
total lengths of tubes formed by 1.42 ± 0.14 and 1.41 ± 0.14 fold,
respectively (ρ < 0.05; Figure 4A). No significant difference was
observed between dalteparin and gsHep treatments. Representative
images of the tube formation experiments are shown in Figure 4B.
These data suggest that gsHep can also promote endothelial function
similarly to dalteparin.
Glycol-split heparin inhibits complement activation
Dalteparin and gsHep were evaluated for the ability to inhibit com-
plement activation. Both dalteparin and gsHep dose-dependently
inhibited complement-mediated hemolysis of sheep erythrocytes,
using serum from preeclamptic patients as the source of comple-
ment. No significant difference was observed between dalteparin and
gsHep treatments. The concentration at which dalteparin and gsHep
inhibited 50% of lytic activity was achieved at 10 μg/mL treat-
ment (P < 0.0001; Figure 5A). To determine whether dalteparin and
gsHep also reduced the generation of the C5a pro-inflammatory ana-
phylatoxin, a C5a ELISA was performed on the hemolytic reaction
supernatant. There was a dose-dependent decrease in the genera-
tion of C5a for both treatments, also achieving approximately 50%
inhibition at 10 μg/mL treatment concentration (P < 0.0001; Fig-
ure 5B). No significant difference between dalteparin and gsHep was
observed. These results suggest that both dalteparin and gsHep may
impact complement activation in a comparable manner.
Glycol-split heparin prevents leukocyte adhesion to
preeclamptic serum-activated endothelial cells
The leukocyte adhesion assay was used to investigate if the hep-
arins can reduce the inflammatory effects of endothelial activation.
As previously reported, preeclamptic serum activated cultured en-
dothelial cells and increased THP-1 monocyte adhesion to the en-
dothelial monolayer [24]. Both dalteparin and gsHep interfered with
the adherence of THP-1 monocytes onto activated endothelial cells
when treatment was incubated with the cells following activation
but prior to seeding of leukocytes (P < 0.01; Figure 6). No signifi-
cant difference between dalteparin and gsHep was observed. These
data suggest that gsHep can also inhibit inflammation mediated by
leukocyte adhesion to activated endothelial cells in preeclampsia.
Discussion
Despite differences in anticoagulant properties, we demonstrate
that the LMWH dalteparin and the nonanticoagulant gsHep ex-
ert similar in vitro placental, endothelial, and anti-inflammatory ef-
fects. Both dalteparin and gsHep stimulate PlGF release from first
trimester placental explants, promote endothelial tube formation
in the presence of placenta conditioned media, inhibit complement
activation, and inhibit leukocyte adhesion to endothelial cells acti-
vated by preeclamptic serum. Overall, these collective actions sug-
gest that both heparins evaluated may be capable of suppressing the
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Figure 2. Differential scanning fluorimetry for sFlt1 and ATIII interactions with dalteparin and gsHep. Both dalteparin and gsHep induced a melting curve shift for
sFlt1, indicating a positive interaction. However, only dalteparin and not gsHep shifted the melting curve for ATIII, indicating the inability for gsHep to interact
with ATIII. ∗∗∗P < 0.0001 compared to no heparin control. n = 3 independent experiments. RFU, relative fluorescence units; sFlt1, soluble fms-like tyrosine
kinase-1; ATIII, antithrombin III.
various pathways that could contribute to the development of severe
preeclampsia.
Placental ischemic injury is a hallmark of severe preeclampsia
[3], and therefore a drug strategy that is designed to support a more
normal physiologic trajectory of placental development is an attrac-
tive approach to preventing the most severe forms of preeclamp-
sia. In accordance with our previous study [13], both dalteparin
and gsHep increased gene expression of PCNA, a proliferation anti-
gen, in whole first trimester placental explants. Restoration of the
physiologic turnover of the villous trophoblast compartment may
be an effective pathway to prevent preeclampsia, as healthy syn-
cytiotrophoblast secretes PlGF into the maternal circulation [25],
which is hypothesized to be protective against this disease [26, 27].
We determined that, similar to dalteparin, gsHep increased the an-
giogenic potential of the conditioned media derived from treated
explants and improved tube formation of cultured endothelial cells
on Matrigel compared to media from untreated explants. This was
accompanied by an increase in PlGF levels in the conditioned me-
dia; while the mechanism has not been well-explored, heparin could
potentially elevate PlGF release by promoting de novo synthesis,
stimulating release of intracellular stores, or displacing cell-surface
heparin-binding PlGF isoforms, such as PlGF-2 or PlGF-4. Previous
investigators have also shown that LMWH enhances trophoblast
differentiation and survival [28, 29] and promotes extravillous tro-
phoblast invasion [30]. Collectively, these data support the hypoth-
esis that LMWH favorably influences placental development and
normalizes angiogenic protein release, which may subsequently al-
leviate the systemic endothelial dysfunction evident in women with
preeclampsia.
sFlt1 is associated with the extracellular matrix, and LMWH
can bind to and displace sFlt1 from endothelial cell surfaces
[31, 32]. Although the in vivo implications of this effect remains
unclear, we speculate that this interaction could disrupt the decoy
action of sFlt1 at the VEGFR2 endothelial cell surface, and con-
tribute to the clearance of excess sFlt1 [31]. Here, we show that, in
the absence of a functional antithrombin-binding region, gsHep can
also bind to sFlt1. Therefore, a nonanticoagulant heparin may, in
theory, be used to facilitate the efficient removal of sFlt1 from the
blood. This mechanism may be equivalent to apheresis of sFlt1 using
a heparin-binding column [33], yet could be safer, more feasible, and
cost-effective.
Widespread host inflammation and complement activation is
present in women with preeclampsia. Activated complement frag-
ments are observable in biological fluids [34–36] and on the pla-
centa, which can play a role in placental damage [37, 38]. Excess
complement activation also occurs in HELLP (hemolysis, elevated
liver enzymes, and low platelet) syndrome, inhibition of which could
lead to disease resolution [39]. Elevated serum levels of the comple-
ment anaphylatoxins such as C5a can also contribute to endothelial
dysfunction [40]. In this study, we showed that both dalteparin and
gsHep can suppress complement activation, leading to reduced lytic
damage to sheep erythrocytes and reduced generation of C5a. Clin-
ically, relevant doses of LMWH have also been shown to suppress
complement activation in vivo [41]. Suppression of complement-
mediated inflammation is therefore a potential mechanism by which
LMWH can confer protection against preeclampsia.
The premise of LMWH therapy for the prevention of
preeclampsia has traditionally been to prevent thrombosis-mediated
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Figure 3. Dalteparin and gsHep elicit similar gene expression and protein release from first trimester placental villous explants. (A) Both treatments dose-
dependently suppressed mRNA levels of PlGF and sFLT1 while increasing mRNA levels of the proliferation gene PCNA. (B) Glycol-split heparin and dalteparin
increased PlGF release into the conditioned media without significantly affecting sFlt1 release. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared to no heparin
controls. n = 6 placenta and media samples. PlGF, placental growth factor; sFlt1, soluble fms-like tyrosine kinase-1; PCNA, proliferating cell nuclear antigen.
Figure 4.Angiogenic effects of placenta conditionedmedia fromdalteparin and gsHep-treated placental explants. (A) Placenta-conditionedmedia fromdalteparin-
or gsHep-treated explants stimulated tube formation from HUVECs on growth factor-reduced Matrigel compared to media from untreated explants. (B) Rep-
resentative images of tube formation were taken from HUVECs treated with media conditioned with 2 μg/mL treatment. ∗P < 0.05 compared to no heparin
controls. n = 5 media samples. Scale bars = 200 μm.
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Figure 5. Anticomplement activity of dalteparin and gsHep. (A) Inclusion of
dalteparin or gsHep in an assay of complement-mediated hemolysis of red
blood cells dose-dependently suppressed lysis. (B) ELISA analyses of the
reaction supernatant also showed a reduction in the generation of the active
C5a pro-inflammatory mediator. Dotted line represents no heparin control. ∗
= dalteparin; # = gsHep. ∗ ,#P < 0.05, ∗∗ ,##P < 0.01, ∗∗∗ ,###P < 0.001 compared
to no heparin control. n = 3 serum samples.
Figure 6. Inhibition of leukocyte adhesion onto activated endothelial cells by
dalteparin and gsHep. Preeclamptic serum stimulated THP-1 monocyte adhe-
sion to HUVECs compared to FBS control (dashed line), and both dalteparin
and gsHep can interfere with this reaction. ∗∗P < 0.01, ∗∗∗P < 0.001 compared
to no heparin control. n = 8 serum samples.
placental damage. However, the strength of the association between
placental thrombotic disease and preeclampsia is controversial [42],
with recent data suggesting only a 25% contribution to disease bur-
den [43]. A wide variety of other factors, including placental dys-
function, cardiovascular status, and inflammation, also contributes
to increased preeclampsia risk, which in turn may be blocked by
nonanticoagulant actions [11]. Interestingly, a recent meta-analysis
suggests that LMWHmay bemost beneficial for at-risk womenwith-
out thrombophilia [44], suggesting that LMWH confers protection
against preeclampsia via nonanticoagulant pathways. This concept
has not been directly investigated. Our validation of gsHep in this
study as an LMWHmimetic without anticoagulant properties serves
as a justification for in vivo experiments to determine specifically
whether the nonanticoagulant effects are therapeutically relevant. A
hypothetical advantage of a nonanticoagulant therapeutic is that it
may permit the use of such heparin derivatives in pregnant women
for the prevention of preeclampsia without incurring significant risk
of bleeding complications.
There are limitations to the interpretation of results related to this
investigation. First, a major limitation is the inherent disadvantages
of in vitro studies, the results of which do not necessarily translate
to the in vivo settings. The current study provides a strong basis
for further investigation into the in vivo relevance of the observed
effects and the anticoagulation-independent actions of heparin for
the prevention of preeclampsia. Second, while gsHep is a very close
approximation to native heparin in biochemical structure, there may
be minor differences that may or may not impact its nonanticoag-
ulant functions. The process of glycol-splitting that yields gsHep
specifically modifies nonsulfated uronic acid residues, which mainly
localizes to the ATBR but may be found scattered throughout the
molecule [19]. It is not knownwhether these modifications outside of
the ATBR will also impact nonanticoagulant properties not assessed
in this study. Furthermore, disruption of the ATBR prevents the in-
activation of the major coagulation enzymes Factor Xa and throm-
bin by heparin-antithrombin complexes. However, these enzymes
may also contribute to additional anticoagulation-independent ef-
fects such as by activating protease-activated receptors on cell sur-
faces or regulating the activity of other proteins through proteolytic
cleavage, among other effects [45]. Thus, these nonanticoagulant
effects may not be fully evaluated by gsHep.
In summary, we have characterized several nonanticoagulant ac-
tions of a modified form of LMWH with minimal ATIII binding
activity. This drug demonstrated promotion of PlGF release by pla-
cental villi, enhanced endothelial cell tube formation exposed to
placenta-conditioned media, inhibition of complement activation,
and suppression of leukocyte adhesion to activated endothelial cells.
These results warrant further investigation and testing of anticoag-
ulant and nonanticoagulant heparin derivatives in appropriate an-
imal models of preeclampsia to evaluate the relevance of nonan-
ticoagulant pathways modulated by LMWH for the prevention of
preeclampsia.
Supplementary data
Supplementary data are available at BIOLRE online.
Supplementary Figure S1.Molecular weight distribution of different
heparin compounds compared to gsHep. Fifty microgram of unfrac-
tionated heparin, enoxaparin, dalteparin, and gsHep were separated
by gel electrophoresis in a 10% tris-borate-EDTA gel and stained
with a 1% solution of alcian blue in 3% acetic acid to visualize sul-
fated glycosaminoglycans. Dalteparin and gsHep exhibited a similar
size distribution compared to enoxaparin, which has a lower average
molecular weight.
Supplementary Figure S2. Differential scanning fluorimetry showed
melting curve shifts of the bonafide heparin-binding growth factors
FGF1 and FGF2 in the presence of either dalteparin or gsHep com-
pared to protein-only curve, indicating a positive interaction.
Supplementary Table S1. List of primers used for qRT-PCR studies.
Supplementary Table S2. Patient characteristics.
D
ow
nloaded from
 https://academ
ic.oup.com
/biolreprod/article-abstract/99/5/1082/5025656 by U
niversity of Aberdeen user on 21 D
ecem
ber 2018
Nonanticoagulant heparin on preeclampsia pathways, 2018, Vol. 99, No. 5 1089
Acknowledgments
The authors thank the donors, the Research Centre for Women’s and Infants’
Health BioBank program, the Lunenfeld-Tanenbaum Research Institute, and
the MSH/University Health Network Department of Obstetrics & Gynaecol-
ogy for the human specimens used in this study.
References
1. American College of Obstetricians and Gynecologists, Task Force on Hy-
pertension in Pregnancy. Hypertension in pregnancy. Report of the Amer-
ican College of Obstetricians and Gynecologists’ Task Force on Hyper-
tension in Pregnancy. Obstet Gynecol 2013; 122:1122–1131.
2. Mitani M, Matsuda Y, Makino Y, Akizawa Y, Ohta H. Clinical features
of fetal growth restriction complicated later by preeclampsia. J Obstet
Gynaecol Res 2009; 35:882–887.
3. Jim B, Karumanchi SA. Preeclampsia: pathogenesis, prevention, and long-
term complications. Semin Nephrol 2017; 37:386–397.
4. Maynard S, Min J, Merchan J, Lim K, Li J, Mondal S, Libermann T, Mor-
gan L, Sellke F, Stillman I, Epstein F, Sukhatme V, et al. Excess placental
soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial
dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest
2003; 111:649–658.
5. Doherty A, Carvalho JCA, Drewlo S, El-Khuffash A, Downey K, Dodds
M, Kingdom J. Altered hemodynamics and hyperuricemia accompany an
elevated sFlt-1/PlGF ratio before the onset of early severe preeclampsia. J
Obstet Gynaecol Can 2014; 36:692–700.
6. Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The
role of aspirin dose on the prevention of preeclampsia and fetal growth
restriction: systematic review and meta-analysis. Am J Obstet Gynecol
2017; 216:110–120.e6. e6.
7. Rodger MA, Carrier M, Le Gal G, Martinelli I, Perna A, Rey E, de
Vries JIP, Gris JC, Low-Molecular-Weight Heparin for Placenta-Mediated
Pregnancy Complications Study Group, Meta-analysis of low-molecular-
weight heparin to prevent recurrent placenta-mediated pregnancy compli-
cations. Blood 2014; 123:822–828.
8. Haddad B, Winer N, Chitrit Y, Houfflin-Debarge V, Chauleur C, Bages K,
Tsatsaris V, Benachi A, Bretelle F, Gris JC, Bastuji-Garin S. Enoxaparin
and aspirin compared with aspirin alone to prevent placenta-mediated
pregnancy complications. Obstet Gynecol 2016; 128:1053–1063.
9. Groom KM, McCowan LM, Mackay LK, Lee AC, Said JM, Kane SC,
Walker SP, van Mens TE, Hannan NJ, Tong S, Chamley LW, Stone PR
et al. Enoxaparin for the prevention of preeclampsia and intrauterine
growth restriction in women with a history: a randomized trial. Am J
Obstet Gynecol 2017; 216:296.e1–296.e14.
10. McLaughlin K, Scholten RR, Parker JD, Ferrazzi E, Kingdom JCP. Low
molecular weight heparin for the prevention of severe preeclampsia: where
next? Br J Clin Pharmacol 2018; 84:673–678.
11. Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Morin F,
Demers C, Kahn SR, Magee LA, Rodger M. Dalteparin for the prevention
of recurrence of placental-mediated complications of pregnancy in women
without thrombophilia: a pilot randomized controlled trial. J Thromb
Haemost 2009; 7:58–64.
12. D’Souza R, Keating S, Walker M, Drewlo S, Kingdom J. Unfraction-
ated heparin and placental pathology in high-risk pregnancies: secondary
analysis of a pilot randomized controlled trial. Placenta 2014; 35:816–
823.
13. Drewlo S, Levytska K, Sobel M, Baczyk D, Lye SJ, Kingdom JCP. Heparin
promotes soluble VEGF receptor expression in human placental villi to
impair endothelial VEGF signaling. J Thromb Haemost 2011; 9:2486–
2497.
14. Di Simone N, Di Nicuolo F, Sanguinetti M, Ferrazzani S, D’Alessio MC,
Castellani R, Bompiani A, Caruso A. Low-molecular weight heparin in-
duces in vitro trophoblast invasiveness: role of matrix metalloproteinases
and tissue inhibitors. Placenta 2007; 28:298–304.
15. Sobel ML, Kingdom J, Drewlo S. Angiogenic response of placental villi to
heparin. Obstet Gynecol 2011; 117:1375–1383.
16. McLaughlin K, Baczyk D, Potts A, Hladunewich M, Parker JD, King-
dom JCP. Low molecular weight heparin improves endothelial function
in pregnant women at high risk of preeclampsia: novelty and significance.
Hypertension 2017; 69:180–188.
17. D’Ippolito S, Marana R, Di Nicuolo F, Castellani R, Veglia M, Stinson
J, Scambia G, Di Simone N. Effect of low molecular weight heparins
(LMWHs) on antiphospholipid antibodies (aPL) - mediated inhibition of
endometrial angiogenesis. PLoS One 2012; 7:1–9.
18. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid
antibody-induced fetal loss by inhibiting complement activation.Nat Med
2004; 10:1222–1226.
19. Casu B, Vlodavsky I, Sanderson RD. Non-anticoagulant heparins and
inhibition of cancer. Pathophysiol Haemos Thromb 2007; 36:195–203.
20. Fransson LÅ, Lewis W. Relationship between anticoagulant activity
of heparin and susceptibility to periodate oxidation. FEBS Lett 1979;
97:119–123.
21. Fragmin (dalteparin sodium) [product monograph]. In Kirkland, Canada:
Pfizer Canada Inc.; 2017.
22. Niesen FH, Berglund H, Vedadi M. The use of differential scanning flu-
orimetry to detect ligand interactions that promote protein stability. Nat
Protoc 2007; 2:2212–2221.
23. Morgan BP. Complement Methods and Protocols [Internet]. Vol. 150.
New Jersey: Humana Press; 2000:61–71.
24. Ryu S, Huppmann AR, Sambangi N, Takacs P, Kauma SW. Increased
leukocyte adhesion to vascular endothelium in preeclampsia is inhibited
by antioxidants. Am J Obstet Gynecol 2007; 196:400.e1–400.e8.
25. Khaliq A, Li XF, Shams M, Sisi P, Acevedo CA, Whittle MJ, Weich H,
Ahmed A. Localisation of placenta growth factor (PlGF) in human term
placenta. Growth Factors 1996; 13:243–250.
26. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L,
Simpson N, Waugh J, Anumba D, Kenny LC, Redman CWG, Shennan
AH. Diagnostic accuracy of placental growth factor in women with sus-
pected preeclampsia: A prospective multicenter study. Circulation 2013;
128:2121–2131.
27. Zhu M, Ren Z, Possomato-Vieira JS, Khalil RA. Restoring placental
growth factor-soluble fms-like tyrosine kinase-1 balance reverses vascular
hyper-reactivity and hypertension in pregnancy.Am J Physiol Regul Integr
Comp Physiol 2016; 311:R505–R521.
28. Bolnick AD, Bolnick JM, Kohan-Ghadr HR, Kilburn BA, Pasalodos OJ,
Singhal PK, Dai J, Diamond MP, Armant DR, Drewlo S. Enhancement
of trophoblast differentiation and survival by low molecular weight hep-
arin requires heparin-binding EGF-like growth factor.HumReprod 2017;
32:1218–1229.
29. Hills FA, Abrahams VM, Gonza´lez-Timo´n B, Francis J, Cloke B, Hinkson
L, Rai R, Mor G, Regan L, Sullivan M, Lam EWF, Brosens JJ. Heparin
prevents programmed cell death in human trophoblast.Mol Hum Reprod
2006; 12:237–243.
30. Tersigni C, Marana R, Santamarı`a A, Castellani R, Scambia G, Di Simone
N. In vitro evidences of heparin’s effects on embryo implantation and
trophoblast development. Reprod Sci 2012; 19:454–462.
31. Hagmann H, Bossung V, Belaidi AA, Fridman A, Karumanchi SA, Thad-
hani R, Schermer B, Mallmann P, Schwarz G, Benzing T, Brinkkoetter
PT. Low-molecular weight heparin increases circulating sFlt-1 levels and
enhances urinary elimination. PLoS One 2014; 9:e85258.
32. Searle J, Mockel M, Gwosc S, Datwyler SA, Qadri F, Albert GI, Holert
F, Isbruch A, Klug L, Muller DN, Dechend R, Muller R, et al. Hep-
arin strongly induces soluble fms-like tyrosine kinase 1 release in vivo
and in vitro–brief report. Arterioscler Thromb Vasc Biol 2011; 31:
2972–2974.
33. Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karu-
manchi SA, Wenger J, Lucchesi KJ, Tamez H, Lindner T, Fridman A,
Thome U, et al. Removal of soluble Fms-like tyrosine kinase-1 by dextran
sulfate apheresis in preeclampsia. J Am Soc Nephrol 2016; 27:903–913.
34. Lynch AM, Murphy JR, Byers T, Gibbs RS, Neville MC, Giclas PC,
Salmon JE, Holers VM. Alternative complement pathway activation frag-
ment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet
Gynecol 2008; 198:385.e1–385.e9.
D
ow
nloaded from
 https://academ
ic.oup.com
/biolreprod/article-abstract/99/5/1082/5025656 by U
niversity of Aberdeen user on 21 D
ecem
ber 2018
1090 J. M. Wat et al., 2018, Vol. 99, No. 5
35. Derzsy Z, Proha´szka Z, Rigo´ J, Fu¨st G, Molvarec A. Activation of the
complement system in normal pregnancy and preeclampsia.Mol Immunol
2010; 47:1500–1506.
36. Burwick RM, Fichorova RN, Dawood HY, Yamamoto HS, Feinberg BB.
Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of
complement activation in pregnancy.Hypertension 2013; 62:1040–1045.
37. Rampersad R, Barton A, Sadovsky Y, Nelson DM. The C5b-9 membrane
attack complex of complement activation localizes to villous trophoblast
injury in vivo andmodulates human trophoblast function in vitro.Placenta
2008; 29:855–861.
38. Buurma A, Cohen D, Veraar K, Schonkeren D, Claas FH, Bruijn JA,
Bloemenkamp KW, Baelde HJ. Preeclampsia is characterized by placental
complement dysregulation. Hypertension 2012; 60:1332–1337.
39. Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclamp-
sia/HELLP syndrome. Placenta 2013; 34:201–203.
40. Lillegard KE, Loeks-Johnson AC, Opacich JW, Peterson JM, Bauer AJ,
Elmquist BJ, Regal RR, Gilbert JS, Regal JF. Differential effects of com-
plement activation products c3a and c5a on cardiovascular function in
hypertensive pregnant rats. J Pharmacol Exp Ther 2014; 351:344–351.
41. Oberkersch R, Attorresi AI, Calabrese GC. Low-molecular-weight heparin
inhibition in classical complement activaton pathway during pregnancy.
Thromb Res 2010; 125:e240–e245.
42. de Maat MPM, de Groot CJM. Thrombophilia and pre-eclampsia. Semin
Thromb Hemost 2011; 37:106–110.
43. Wright E, Audette MC, Ye XY, Keating S, Hoffman B, Lye SJ, Shah PS,
Kingdom JC. Maternal vascular malperfusion and adverse perinatal out-
comes in low-risk nulliparous women. Obstet Gynecol 2017; 130:1112–
1120.
44. Rodger MA, Gris JC, de Vries JIP, Martinelli I, Rey E´, Schleussner E,
Middeldorp S, Kaaja R, Langlois NJ, Ramsay T, Mallick R, Bates SM,
et al. Low-molecular-weight heparin and recurrent placenta-mediated
pregnancy complications: a meta-analysis of individual patient data
from randomised controlled trials. Lancet North Am Ed 2016; 388:
2629–2641.
45. Ebrahimi S, Rahmani F, Behnam-Rassouli R, Hoseinkhani F, Parizadeh
MR, Keramati MR, Khazaie M, Avan A, Hassanian SM. Proinflammatory
signaling functions of thrombin in cancer. J Cell Physiol 2017; 232:2323–
2329.
D
ow
nloaded from
 https://academ
ic.oup.com
/biolreprod/article-abstract/99/5/1082/5025656 by U
niversity of Aberdeen user on 21 D
ecem
ber 2018
